Johnson & Johnson Stock News

Pecan, a startup that''s developing an AI-powered analytics platform for customers like Johnson & Johnson, has raised $XXX.

Native American tribes have reached a $590 million settlement with Johnson & Johnson and three drug distributors over opioid overdoses Read Full Article at RT.com

The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 867 13F filings that hedge funds and well-known value investors are required to file by the SEC.

It''s the largest opioid settlement for Native Americans.

Johnson & Johnson and the country''s three major drug distributors agreed Tuesday to pay $590 million to Native American tribes affected by the opioid crisis, according to a proposed settlement . Why it matters: It''s the largest opioid settlement for Native Americans, the Washington Post notes. "American Indians have suffered the highest per capita rate of opioid overdose and are more likely than other group in the United States to die from drug-induced deaths," said Douglas Yankton, chair of the Spirit Lake Nation in North Dakota, in a statement, per AP . "The dollars that will flow to Tribes under this initial settlement will help fund crucial, on-reservation, culturally appropriate opioid treatment services," Yankton added. The big picture: More than 400 tribes sued the companies, alleging that they helped fuel abuse of the addictive painkillers, Bloomberg reports. By the numbers: In Tuesday''s settlement, distributors McKesson, Cardinal Health and AmerisourceBergen have agreed to pay $440 million over seven years to tribes that have been disproportionately impacted by the opioid crisis.

More than 400 Native American tribes reached a $590-million settlement Tuesday with Johnson & Johnson and three other drug distributors, according to court documents filed in U.S. District Court in Cleveland.

Tribes were disproportionately affected by the opioid epidemic.

Filing involves Johnson & Johnson and three big distributors as attorney general for eight states and DC close to deal with Purdue

Shares of Novavax Inc. rallied 10.0% in trading on Monday after the company said it filed for authorization of its experimental COVID-19 shot in the U.S. Novavax''s COVID-19 vaccine candidate is protein-based, meaning it''s a different type of vaccine than the mRNA shots developed by BioNTech SE /Pfizer Inc. and Moderna Inc. or the Johnson & Johnson viral vector vaccine. Novavax said it is seeking authorization for its two-dose vaccine in adults, based on two clinical studies. One Phase 3 trial assessing the vaccine in about 15,000 adults in the U.K. reported an 89.7% efficacy rate against infection with the virus, according to research published in the New England Journal of Medicine in September. A second trial that enrolled about 30,000 adults in the U.S. and Mexico found that shots produced an efficacy rate of 92.6% against any variants of concern or interest. That study was also published in the New England Journal of Medicine, in December. Some of the vaccine''s side effects include headache, pain at the injection site, and fatigue.

Dublin, Jan. 31, 2022 (GLOBE NEWSWIRE) -- The "Urinary Incontinence Market by Product, Incontinence Type, and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com''s offering. The global urinary incontinence market was valued at $10,124.33 million in 2020, and is projected to reach $19,341.15 million by 2030, registering a CAGR of 6.8% from 2021 to 2030. The involuntary flow of urine due to a loss of bladder control is known as urinary incontinence. Urinary incontinence devices aid in collecting and holding urine; such devices help in managing urinary incontinence effectively. People undergoing urinary incontinence suffer from urine leakage that cannot be controlled. Patients suffering from severe urinary incontinence are recommended surgical treatment that incorporates devices such as urinary catheter, vaginal slings, electrical stimulation devices, and artificial urinary sphincters. Among the aforementioned incontinent devices, the most evidently used devices include indwelling catheters, external collecting systems, urine drainage bags, and catheters for intermittent catheterization (IC).

PALM BEACH, Fla. , Jan. 27, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018, breast cancer ranks as the fifth leading cause of deaths in women; accounting for 627,000 deaths every year. Moreover, as per estimates of the American Cancer Society, in U.S., 266,120 new cases were expected to be diagnosed in women by 2018. Furthermore, aging is considered as one of the greatest risk factors. According to Cancer Treatment Centers of America, women above 60 years of age are more likely to be diagnosed and only about 10% to 15% of cases occur in women younger than 45 years of age. High prevalence of the disease coupled with patent expiry are some of the major factors influencing investment in research and development of new products. The R&D spending from companies like Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Celgene Corporation; Pfizer, Inc.; GlaxoSmithKline plc; Sanofi; and AbbVie, Inc. has increased exponentially.

Most of the U.S. cities and counties have agreed to a proposed deal worth up to $26B involving Johnson & Johnson (JNJ) and three leading drug distributors in the U.S